New research indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional diet and exercise plans.
Published data in a leading medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these drugs need to be aware of the danger of quick weight regain when the treatment concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original weight in about one and a half years.
Analyzing Treatments
The study, which examined 37 of trials involving thousands of participants, contrasted the results of the injectable medications with other pills.
Scientists note that individuals who lose weight through diet and exercise generally see a more gradual creep back—around 0.1 kg a month—once they finish.
Understanding the Quick Regain
Experts propose the mode of action of the injections accounts for the accelerated regain.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who say that the findings "underscore the long-term character of obesity," akin to managing conditions like high blood pressure.
User Accounts
Users who have come off the jabs describe a sudden return of cravings.
"It was like something activating and you become extremely hungry," recalled an individual.
This challenge is worsened if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Interest
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
Finally, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and long-term success hinges on ongoing lifestyle support.
